Etanercept, a TNF-alpha binding agent, is ineffective in the prevention of post-ERCP pancreatitis in canines

Journal of the Pancreas

Volumn 9, Issue 4, 2008, Pages 456-467

  Buscaglia, Jonathan M ^a   Simons, Brian W ^a   Prosser, Brent J ^a   Ruben, Dawn S ^a   Giday, Samuel A ^a   Magno, Priscilla ^a   Clarke, John O ^a   Shin, Eun Ji ^a   Kalloo, Anthony N ^a   Kantsevoy, Sergey V ^a   Gabrielson, Katheen L ^a   Jagannath, Sanjay B ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cholangiopancreatography; Dogs; Endoscopic retrograde; Pancreatitis

Indexed keywords

AMYLASE; ETANERCEPT; TRIACYLGLYCEROL LIPASE; TRYPSINOGEN ACTIVATION PEPTIDE; TUMOR NECROSIS FACTOR ALPHA;

AMYLASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOPSY; CONTROLLED STUDY; CREATININE URINE LEVEL; DRUG TREATMENT FAILURE; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; EXPERIMENTAL DOG; HYPERAMYLASEMIA; INJURY SCALE; MALE; NONHUMAN; PANCREATITIS; POSTOPERATIVE PERIOD; PROTEIN BLOOD LEVEL; RELIABILITY; SCORING SYSTEM; TREATMENT OUTCOME; TRIACYLGLYCEROL LIPASE BLOOD LEVEL;

AMYLASES; ANIMALS; CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE; DISEASE MODELS, ANIMAL; DOGS; IMMUNOGLOBULIN G; LIPASE; OLIGOPEPTIDES; PANCREAS; PANCREATITIS; RECEPTORS, TUMOR NECROSIS FACTOR; TREATMENT FAILURE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 48949104529     PISSN: None     EISSN: 15908577     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Ruppin H, Amon R, Ettl W, Classen M, Demling L. Acute pancreatitis after endoscopic/radiological pancreatography (ERP). Endoscopy 1974; 6:94-8.
2. Pfau PR, Mosley RG, Said A, Gopal DV, Fischer MC, Oberley T, et al. Comparison of the effect of non-ionic and ionic contrast agents on pancreatic histology in a canine model. JOP. J Pancreas (Online) 2006; 7:27-33.
3. Cheng CL, Sherman S, Watkins JL, Barnett J, Freeman M, Geenen J, et al. Risk factors for post-ERGP pancreatitis: a prospective multicenter study. Am J Gastroenterol 2006; 101:139-47.
4. Yadav D, Agarwal N, Pitchumoni CS. A critical evaluation of laboratory tests in acute pancreatitis. Am J Gastroenterol 2002; 97:1309-18.
5. Viedma JA, Pérez-Mateo M, Dominguez JE, Carballo F. Role of interleukin-6 in acute pancreatitis. Comparison with C-reactive protein and phospholipase A. Gut 1992; 33:1264-7.
6. Rau B, Steinbach G, Gansauge F, Mayer JM, Grünert A, Beger HG. The potential role of procalcitonin and interleukin 8 in the prediction of infected necrosis in acute pancreatitis. Gut 1997; 41:832-40.
7. Devière J, Le Moine O, Van Laethem JL, Eisendrath P, Ghilain A, Severs N, Cohard M. Interleukin 10 reduces the incidence of pancreatitis after therapeutic endoscopic retrograde cholangiopancreatography. Gastroenterology 2001; 120:498-505.
8. Pezzilli R, Billi P, Miniero R, Fiocchi M, Cappelletti O, Morselli-Labate AM, et al. Serum interleukin-6, interleukin-8, and beta 2-microglobulin in early assessment of severity of acute pancreatitis. Comparison with serum C-reactive protein. Dig Dis Sci 1995; 40:2341-8.
9. de Beaux AC, Goldie AS, Ross JA, Carter DC, Fearon KC. Serum concentrations of inflammatory mediators related to organ failure in patients with acute pancreatitis. Br J Surg 1996; 83:349-53.
10. Chen CC, Wang SS, Lee FY, Chang FY, Lee SD. Proinflammatory cytokines in early assessment of the prognosis of acute pancreatitis. Am J Gastroenterol 1999; 94:213-8.
11. Oruc N, Ozutemiz AO, Yukselen V, Nart D, Celik HA, Yuce G, Batur Y. Infliximab: a new therapeutic agent in acute pancreatitis? Pancreas 2004; 28:e1-8.
12. Malleo G, Mazzon E, Genovese T, Di Paola R, Muia C, Centorrino T, et al. Etanercept attenuates the development of cerulein-induced acute pancreatitis in mice: a comparison with TNF-alpha genetic deletion. Shock 2007, 27:542-51.
13. Buscaglia JM, Simons BW, Prosser BJ, Ruben DS, Giday SA, Magno P, et al. Severity of post-ERCP pancreatitis directly proportional to the invasiveness of endoscopic intervention: a pilot study in a canine model. Endoscopy 2008; 40:506-12.
14. Evans HE. The digestive apparatus and abdomen. In: Miller's Anatomy of the Dog 2nd Ed. Philadelphia, PA, USA: Saunders, 1982:456-60.
15. Newman SJ, Steiner JM, Woosley K, Williams DA, Barton L. Histologic assessment and grading of the exocrine pancreas in the dog. J Vet Diagn Invest 2006; 18:115-8.
16. Cavallini G, Tittobello A, Frulloni L, Masci E, Mariana A, Di Francesco V. Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography. Gabexate in digestive endoscopy-Italian Group. N Engl J Med 1996; 335:919-23.
17. Katsinelos P, Kountouras J, Chatzis J, Christodoulou K, Paroutoglou G, Mimidis K, et al. High-dose allopurinol for prevention of post-ERCP pancreatitis: a prospective randomized double-blind controlled trial. Gastrointest Endosc 2005; 61:407-15.
18. Murray B, Carter R, Imrie C, Evans S, O'Suilleabhain C. Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography. Gastroenterology 2003; 124:1786-91.
19. Sudhindran S, Bromwich E, Edwards PR. Prospective randomized double-blind placebo-controlled trial of glyceryl trinitrate in endoscopic retrograde cholangiopancreatography-induced pancreatitis. Br J Surg 2001; 88:1178-82.
20. Binmoeller KF, Harris AG, Dumas R, Grimaldi C, Delmont JP. Does the somatostatin analogue octreotide protect against ERCP induced pancreatitis? Gut 1992; 33:1129-33.
21. Prat F, Amaris J, Ducot B, Bocquentin M, Fritsch J, Choury AD, et al. Nifedipine for prevention of post-ERCP pancreatitis: a prospective, double-blind randomized study. Gastrointest Endosc 2002; 56:202-8.
22. Sand J, Nordback I. Prospective randomized trial of the effect of nifedipine on pancreatic irritation after endoscopic retrograde cholangiopancreatography. Digestion 1993; 54:105-11.
23. Weiner GR, Geenen JE, Hogan WJ, Catalano NF. Use of corticosteroids in the prevention of post-ERCP pancreatitis. Gastrointest Endosc 1995; 42:579-83.
24. Budzyńska A, Marek T, Nowak A, Kaczor R, Nowakowska-Dulawa E. A prospective, randomized, placebo-controlled trial of prednisone and allopurinol in the prevention of ERCP-induced pancreatitis. Endoscopy 2001; 33:766-72.
25. De Palma GD, Catanzano C. Use of corticosteriods in the prevention of post-ERCP pancreatitis: results of a controlled prospective study. Am J Gastroenterol 1999; 94:982-5.
26. Dumot JA, Conwell DL, O'Connor JB, Ferguson DR, Vargo JJ, Barnes DS, et al. Pretreatment with methylprednisolone to prevent ERCP-induced pancreatitis: a randomized, multicenter, placebo-controlled clinical trial. Am J Gastroenterol 1998; 93:61-5.
27. Sherman S, Blaut U, Watkins JL, Barnett J, Freeman M, Geenen J, et al. Does prophylactic administration of corticosteroid reduce the risk and severity of post-ERCP pancreatitis: a randomized, prospective, multicenter study. Gastrointest Endosc 2003; 58:23-9.
28. Manolakopoulos S, Avgerinos A, Vlachogiannakos J, Armonis A, Viazis N, Papadimitriou N, et al. Octreotide versus hydrocortisone versus placebo in the prevention of post-ERCP pancreatitis: a multicenter randomized controlled trial. Gastrointest Endosc 2002; 55:470-5.
29. Rongione AJ, Kusske AM, Kwan K, Ashley SW, Reber HA, McFadden DW. Interleukin 10 reduces the severity of acute pancreatitis in rats. Gastroenterology 1997; 112:960-7.
30. Van Laethem JL, Marchant A, Delvaux A, Goldman M, Robberecht P, Velu T, Devière J. Interleukin 10 prevents necrosis in murine experimental acute pancreatitis. Gastroenterology 1995; 108:1917-22.
31. Dumot JA, Conwell DL, Zuccaro G Jr, Vargo JJ, Shay SS, Easley KA, Ponsky JL. A randomized, double blind study of interleukin 10 for the prevention of ERCP-induced pancreatitis. Am J Gastroenterol 2001; 96:2098-102.
32. Arvanitidis D, Anagnostopoulos GK, Giannopoulos D, Pantes A, Agaritsi R, Margantinis G, et al. Can somatostatin prevent post-ERCP pancreatitis? Results of a randomized controlled trial. J Gastroenterol Hepatol 2004; 19:278-82.
33. Bordas JM, Toledo-Pimentel V, Llach J, Elena M, Mondelo F, Ginès A, Terés J. Effects of bolus somatostatin in preventing pancreatitis after endoscopic pancreatography: results of a randomized study. Gastrointest Endosc 1998; 47:230-4.
34. Poon RT, Yeung C, Lo CM, Yuen WK, Liu CL, Fan ST. Prophylactic effect of somatostatin on post-ERCP pancreatitis: a randomized controlled trial. Gastrointest Endosc 1999; 49:593-8.
35. Sternlieb JM, Aronchick CA, Retig JN, Dabezies M, Saunders F, Goosenberg E, et al. A multicenter, randomized, controlled trial to evaluate the effect of prophylactic octreotide on ERCP-induced pancreatitis. Am J Gastroenterol 1992; 87:1561-6.
36. Testoni PA, Bagnolo F, Andriulli A, Bernasconi G, Crotta S, Lella F, et al. Octreotide 24-h prophylaxis in patients at high risk for post-ERCP pancreatitis: results of a multicenter, randomized, controlled trial. Aliment Pharmacol Ther 2001; 15:965-72.
37. Testoni PA. Facts and fiction in the pharmacologic prevention of post-ERCP pancreatitis: a never-ending story. Gastrointest Endosc 2006; 64:732-4.
38. Hughes CB, Grewal HP, Gaber LW, Kotb M, Eldin AB, Mann L, Gaber AO. Anti-TNFalpha therapy improves survival and ameliorates the pathophysiologic sequelae in acute pancreatitis in the rat. Am J Surg 1996; 171:274-80.
39. Hughes CB, Gaber LW, Kotb M, Mohey el-Din AB, Pabst M, Gaber AO. Induction of acute pancreatitis in germ-free rats: evidence of a primary role for tumor necrosis factor-alpha. Surgery 1995; 117:201-5.
40. Hughes CB, Henry J, Kotb M, Lobaschevsky A, Sabek O, Gaber AO. Up-regulation of TNF alpha mRNA in the rat spleen following induction of acute pancreatitis. J Surg Res 1995; 59:687-93.
41. Grewal HP, Mohey el Din A, Gaber L, Kotb M, Gaber AO. Amelioration of the physiologic and biochemical changes of acute pancreatitis using an anti-TNF-alpha polyclonal antibody. Am J Surg 1994; 167:214-9.
42. Hughes CB, Gaber LW, Mohey el-Din AB, Grewal HP, Kotb M, Mann L, Gaber AO. Inhibition of TNF alpha improves survival in an experimental model of acute pancreatitis. Am Surg 1996; 62:8-13.
43. Qin HL, Su ZD, Gao Q, Lin QT. Early intrajejunal nutrition: bacterial translocation and gat barrier function of severe acute pancreatitis in dogs. Hepatobiliary Pancreat Dis Int 2002; 1:150-4.
44. Chen J, Wang XP, Liu P, Wu K, Xu M, Yu XF, Wang GS. Effects of continuous early enteral nutrition on the gut barrier function in dogs with acute necrotizing pancreatitis. Zhonghua Yi Xue Za Zhi 2004; 84:1726-31.
45. Zhu Q, Yuan Y, Xia L, Xu J. The effect of sandostatin on sphincter of Oddi in acute severe pancreatitis in dogs. Zhonghua Nei Ke Za Zhi 1999; 38:747-9.
46. Ruaux CG, Pennington HL, Worrall S, Atwell RB. Tumor necrosis factor-alpha at presentation in 60 cases of spontaneous canine acute pancreatitis. Vet Immunol Immunopathol 1999; 72:369-376.